Patricia Giblin

Patricia Giblin

Company: Revitope

Job title: VP of Biology



Dr. Giblin joined Revitope Oncology in July 2019 as VP Biology.  She is an experienced leader in drug discovery and development with strong track record for delivering biologic and small molecule candidates into the clinic in immune oncology and immunology.  Prior to joining Revitope, Patricia was a Senior Director of Translational Sciences at Northern Biologics where she played a key role in delivering the translational strategy and leading the company’s first clinical program.  Patricia began her career at Boehringer Ingelheim Pharmaceuticals, Inc. where she spent several years working in both Research and Development.  She obtained her Ph.D. in Immunology from Yale University and conducted her postdoctoral studies at UCSF in the laboratory of Dr. Steven D. Rosen


T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index 10:00 am

Traditional T cell redirecting therapies can kill tumor cells in therapeutically useful ways but are limited by off-target and on-target/off-tumor toxicities The goal of the TEAC platform is to focus T cell redirection to the tumor and limit T cell driven toxicities in the periphery to improve therapeutic index and expand treatment opportunities in both…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.